Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study - Summary - MDSpire
Advertisement
Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study
To evaluate the safety, immune response, and specific long COVID effects of inactivated COVID-19 vaccine boosters in adults aged ≥60 years.
Key Findings:
Low incidence of adverse reactions (0.0%–8.0%), with more local reactions in CoronaVac-S3 recipients (P = 0.0124).
Highest geometric mean titers (GMTs) of neutralizing antibodies observed in S3 groups at 1 month post vaccination (P<0.001).
Covilo-S2 and -S3 showed superior inhibition against wild-type and Delta variants compared to CoronaVac counterparts (all P<0.05).
Male sex identified as a protective factor against COVID-19 symptoms, long COVID, and fatigue (odds ratios <0.5 and P<0.05 for all).
Interpretation:
A third booster of inactivated SARS-CoV-2 vaccine is safe and significantly enhances humoral immunity in older adults, with specific regimens optimizing immunogenicity and reducing risks of COVID-19 symptoms and long COVID.
Limitations:
Study conducted in a single region (Zhejiang Province, China), which may limit generalizability and introduce potential biases.
Follow-up duration of 12 months may not capture long-term effects.
Conclusion:
The three-dose Covilo regimen administered within 2–6 months of the second dose is optimal for boosting immunity in older adults, emphasizing the need for tailored vaccination strategies to address specific population needs.
Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.
